DOCSLIB.ORG

Comparative Effectiveness of In-Hospital Use of Recombinant

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Comparative Effectiveness of In-Hospital Use of Recombinant AHRQ%Systematic%Review%% Surveillance%Program% " CER$#21:$Comparative"Effectiveness"of"In2Hospital" Use"of"Recombinant"Factor"VIIa"for"Off2Label" Indications"vs"Usual"Care" $ $ Original$Release$Date:$May"2010" Surveillance$Report:"February"2012""" Surveillance$Report:"August"2016" $ Summary$of$Key$Findings$from$Surveillance$ Report:$ •" Key$Question$1:"Conclusions"are"likely"current."" •" Key$Question$2:"Conclusions"are"likely"current."" •" Key$Question$3a:"Conclusions"are"likely"current."" •" Key$Question$3B:"Conclusions"are"likely"current."" •" Key$Question$4a:"Conclusions"are"likely"current."$ •" Key$Question$4B.i:"Conclusions"are"likely"current."$ •" Key$Question$4B.ii:$Conclusions"are"likely"current."$ •" Key$Question$4c:"Conclusions"are"likely"current."One"expert"noted" prostatectomy"is"now"associated"with"lower"morbidity"due"to"the"use" of"laparoscopic"and"robotic"technology,"which,"although"unrelated"to" conclusions"on"the"off2label"use"of"rFVIIa,"provides"important"context" of"how"the"morbidity"associated"with"this"surgical"procedure"has" changed"over"time.$$ " Signal$Assessment:"The"signal"for"this"report"is"weak"suggesting"that" the"conclusions"in"the"original"systematic"review"are$up$to$date.$$ i" Authors:$" Stephanie"Veazie" Karli"Kondo" Kara"Winchell"" " Conflict$of$Interest:$ None"of"the"investigators"has"any"affiliations"or"financial"involvement"that"conflicts"with" the"material"presented"in"this"report."" " Acknowledgements:$ The"authors"gratefully"acknowledge"the"following"individuals"for"their"contributions"to" this"project:"Rose"Relevo"for"conducting"searches." ii" Reviewers$ " Richard"P."Dutton,"MD,"MBA" Professor" Department"of"Anesthesiology" University"of"Maryland"School"of"Medicine" Baltimore,"MD" " Maureane"Hoffman,"MD,"PhD" Professor" Department"of"Pathology" Duke"University"School"of"Medicine" Durham,"NC"" " " " " " " " " " " " " " " " " " " " " " " " " " " $ " iii" Table$of$Contents$ Introduction"..................................................................................................................................."1" Methods"........................................................................................................................................"1" Prior"Surveillance"......................................................................................................................"1" Literature"Searches".................................................................................................................."2" Study"Selection"........................................................................................................................."2" Expert"Opinion".........................................................................................................................."2" FDA,"Health"Canada,"and"MHRA"Warnings"............................................................................."3" Check"for"Qualitative"Signals"...................................................................................................."3" Signal"Assessment"for"Currency"of"the"Systematic"Review"....................................................."4" Results"........................................................................................................................................."4" Prior"Surveillance"......................................................................................................................"4" Literature"Search"......................................................................................................................"5" FDA,"Health"Canada,"and"MHRA"Black"Box"Warnings"............................................................"5" Expert"Opinion".........................................................................................................................."5" Identifying"Qualitative"Signals"..................................................................................................."6" Signal"Assessment"..................................................................................................................."7" References"..................................................................................................................................."9" Appendices"................................................................................................................................."11" Appendix"A."Search"Strategy"................................................................................................."A21" Appendix"B."Inclusion"and"Exclusion"Criteria"from"Original"Systematic"Review"..................."B21" Appendix"C."Literature"Search"Results".................................................................................."C21" Appendix"D."Questionnaire"Sent"to"Expert"Reviewers".........................................................."D21" Abstracts"from"Relevant"Literature/References"..............................................................."D219" Appendix"E."Summary"Table"................................................................................................."E21" References"......................................................................................................................."E222" " $ $ $ " iv" Introduction$$ The"purpose"of"the"surveillance"process"for"the"EPC"Program"is"to"determine"whether"the" conclusions"of"a"systematic"review"are"current."The"surveillance"process"examines"the" conclusions"to"the"key"questions"as"written,"and"does"not"evaluate"the"currency"of"the"original" scope"(i.e.,"key"questions,"included"interventions)."Approximately"25"systematic"reviews"are" selected"for"surveillance"annually"based"on"popularity,"use"in"obtaining"continuing"medical" education"certificates,"potential"impact"for"changing"the"field,"and"use"in"clinical"practice" guidelines." " Comparative"Effectiveness"Review"(CER)"#21"titled"Comparative+Effectiveness+of+In2Hospital+ Use+of+Recombinant+Factor+VIIa+for+Off2Label+Indications+vs+Usual+Care,"was"originally"released" in"May"2010.1"" " The"key"questions"for"the"original"systematic"review"are"as"follows:"" " Key$Question$1.$Indications,"Populations,"and"Characteristics"of"Comparative"Studies"of"Off2 Label"rFVIIa"Use?" " Key$Question$2."Use"of"rFVIIa"for"Selected"Indications"in"Individuals"With/Undergoing" Intracranial"Hemorrhage" " Key$Question$3a."Use"of"rFVIIa"for"Selected"Indications"in"Individuals"With/Undergoing" Massive"Bleeding"from"Trauma"(Body"Trauma)" " Key$Question$3B."Use"of"rFVIIa"for"Selected"Indications"in"Individuals"With/Undergoing" Massive"Bleeding"from"Trauma"(Brain"Trauma)"i.e.,"Traumatic"Brain"Injury"[TBI])" " Key$Question$4a."Use"of"rFVIIa"for"Selected"Indications"in"Individuals"With/Undergoing"Liver" Transplantation" " Key$Question$4B.i."Use"of"rFVIIa"for"Selected"Indications"in"Individuals"With/Undergoing" Cardiac"Surgery"(Adult"Cardiac"Surgery)" " Key$Question$4B.ii."Use"of"rFVIIa"for"Selected"Indications"in"Patient"With/Undergoing"Cardiac" Surgery"(Pediatric"Cardiac"Surgery)" " Key$Question$4c."Use"of"rFVIIa"for"Selected"Indications"in"Patient"With/Undergoing" Prostatectomy" " Our"surveillance"assessment"began"in"December"2015."We"conducted"an"electronic"search"for" literature"published"since"the"end"date"of"the"most"recent"surveillance"report"search"date."After" completing"a"scan"of"this"literature"to"identify"evidence"potentially"related"to"the"key"questions"in" this"systematic"review,"we"contacted"experts"involved"in"the"original"systematic"review"to" request"their"opinions"as"to"whether"the"conclusions"had"changed." " MetHods$$ $ Prior$Surveillance$$ " 1" A"surveillance"report"for"the"original"systematic"review"was"released"in"February"2012,"and" included"a"search"for"relevant"literature"published"from"20082Jan"2012"among"five"general" medical"journals"(Annals"of"Internal"Medicine,"BMJ,"JAMA,"Lancet,"and"New"England"Journal"of" Medicine)"and"five"specialty"journals"(Journal"of"Trauma"Injury,"Infection"and"Critical"Careg" NeurocriticalCareg"Annals"of"Thoracic"Surgeryg"Transplantationg"and"Stroke),"expert"opinion," and"a"search"of"U.S."Food"and"Drug"Administration"(FDA)"surveillance"alerts"received"from"the" Emergency"Care"Research"Institute"(ECRI)."The"findings"from"this"report"are"included"in"our" assessment."" $ Literature$Searches$$ " We"conducted"a"literature"search"of"Ovid"MEDLINE"covering"January"2012"to"December"2015" using"the"identical"search"strategy"used"for"the"original"review1"and"searching"for"studies" published"since"the"end"date"of"the"most"recent"surveillance"search." " The"literature"search"to"assess"the"currency"of"conclusions"was"conducted"among"a"selection"of" the"top"10"high"profile"general"medical"interest"journals"and"specialty"journals"searched"in"2012" surveillance"report"(Annals"of"Internal"Medicineg"Annals"of"Thoracic"Surgeryg"BMJg"JAMA," Journal"of"Trauma"Injury,"Infection"and"Critical"Careg"Lancetg"Neurocritical"Careg"New"England" Journal"of"Medicineg"Strokeg"Transplantation)."However,"because"the"search"yielded"fewer"than" 10"studies,"we"removed"the"journal"limitations."The"search"strategy"is"reported"in"Appendix"A."" $ Study$Selection$$ " We"used"the"same"inclusion"and"exclusion"criteria"as"the"original"systematic"review,"with"one" exception."The"original"review"included"an"evaluation"of"the"Premier"database"from"200022008" to"“document"the"complete"range"of"clinical"indications"where"rFVIIa"is"being"used"off2label," including"information"on"real2world"in2hospital"practice"patterns”"(p."9).1"In"lieu"of"conducting"an" updated"analysis"of"the"Premier"database,"we"expanded"the"inclusion"criteria"for"the"first"
Load more

Recommended publications
  • Cross-Linking of Alpha 2-Plasmin Inhibitor to Fibrin by Fibrin- Stabilizing Factor
    Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin- stabilizing factor. Y Sakata, N Aoki J Clin Invest. 1980;65(2):290-297. https://doi.org/10.1172/JCI109671. Research Article The concentration of alpha 2-plasmin inhibitor in blood plasma is higher than that in serum obtained from the blood clotted in the presence of calcium ions, but is the same as that in serum obtained in the absence of calcium ions. Radiolabeled alpha2-plasmin inhibitor was covalently bound to fibrin only when calcium ions were present at the time of clotting of plasma or fibrinogen. Whereas, when batroxobin, a snake venom enzyme that lacks the ability to activate fibrin- stabilizing factor, was used for clotting fibrinogen, the binding was not observed. When fibrin-stablizing, factor-deficient plasma was clotted, the specific binding of alpha 2-plasmin inhibitor to fibrin did not occur even in the presence of calcium ions and the concentration of alpha 2-plasmin inhibitor in serum was the same as that in plasma. Monodansyl cadaverine, a fluorescent substrate of the fibrin-stablizing factor, was incorporated into alpha 2-plasmin inhibitor by activated fibrin-stablizing factor. All these findings indicate that alpha 2-plasmin inhibitor is cross-linked to fibrin by activated fibrin-stabilizing factor when blood is clotted. Analysis of alpha 2-plasmin inhibitor-incorporated fibrin by sodium dodecyl sulfate gel electrophoresis showed that the inhibitor was mainly cross-linked to polymerized alpha-chains of cross-linked fibrin. Cross-linking of alpha 2-plasmin inhibitor to fibrin renders fibrin clot less susceptible to fibrinolysis by plasmin.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 6,019,993 Bal (45) Date of Patent: Feb
    USOO6O19993A United States Patent (19) 11 Patent Number: 6,019,993 Bal (45) Date of Patent: Feb. 1, 2000 54) VIRUS-INACTIVATED 2-COMPONENT 56) References Cited FIBRIN GLUE FOREIGN PATENT DOCUMENTS 75 Inventor: Frederic Bal, Vienna, Austria O 116 263 1/1986 European Pat. Off.. O 339 607 4/1989 European Pat. Off.. 73 Assignee: Omrix Biopharmaceuticals S.A., O 534 178 3/1993 European Pat. Off.. Brussels, Belgium 2 201993 1/1972 Germany. 2 102 811 2/1983 United Kingdom. 21 Appl. No.: 08/530,167 PCTUS85O1695 9/1985 WIPO. PCTCH920.0036 2/1992 WIPO. 22 PCT Filed: Mar. 27, 1994 PCT/SE92/ 00441 6/1992 WIPO. 86 PCT No.: PCT/EP94/00966 PCTEP9301797 7/1993 WIPO. S371 Date: Nov.30, 1995 Primary Examiner-Carlos Azpuru Attorney, Agent, or Firm-Jacobson, Price, Holman, & S 102(e) Date: Nov.30, 1995 Stern, PLLC 87 PCT Pub. No.: WO94/22503 57 ABSTRACT PCT Pub. Date: Oct. 13, 1994 A two-component fibrin glue for human application includes 30 Foreign Application Priority Data a) a component A containing i) a virus-inactivated and concentrated cryoprecipitate that contains fibrinogen, and ii) Mar. 30, 1993 EP European Pat. Off. .............. 93105298 traneXamic acid or a pharmaceutically acceptable Salt, 51 Int. Cl." A61F 2/06; A61K 35/14 thereof, and b) component B containing a proteolytic 52 U s C - - - - - - - - - - - - - - - - - - - - - - - - - - -424/426. 530,380, 530/381: enzyme that, upon combination with component A, cleaves, O X O -- O - - - s 530(383. 530ass Specifically, fibrinogen present in the cryoprecipitate of 58) Field of Search 424/426,530,380 component A, thereby, effecting a fibrin polymer.
    [Show full text]
  • Safety and Efficacy of Prothrombin Complex Concentrate As First-Line
    Cappabianca et al. Critical Care (2016) 20:5 DOI 10.1186/s13054-015-1172-6 RESEARCH Open Access Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery Giangiuseppe Cappabianca1†, Giovanni Mariscalco2*† , Fausto Biancari3, Daniele Maselli4, Francesca Papesso1, Marzia Cottini1, Sandro Crosta5, Simona Banescu5, Aamer B. Ahmed6 and Cesare Beghi1 Abstract Background: Bleeding after cardiac surgery requiring surgical reexploration and blood component transfusion is associated with increased morbidity and mortality. Although prothrombin complex concentrate (PCC) has been used satisfactorily in bleeding disorders, studies on its efficacy and safety after cardiopulmonary bypass are limited. Methods: Between January 2005 and December 2013, 3454 consecutive cardiac surgery patients were included in an observational study aimed at investigating the efficacy and safety of PCC as first-line coagulopathy treatment as a replacement for fresh frozen plasma (FFP). Starting in January 2012, PCC was introduced as solely first-line treatment for bleeding following cardiac surgery. Results: After one-to-one propensity score–matched analysis, 225 pairs of patients receiving PCC (median dose 1500 IU) and FFP (median dose 2 U) were included. The use of PCC was associated with significantly decreased 24-h post-operative blood loss (836 ± 1226 vs. 935 ± 583 ml, p < 0.0001). Propensity score–adjusted multivariate analysis showed that PCC was associated with significantly lower risk of red blood cell (RBC) transfusions (odds ratio [OR] 0.50; 95 % confidence interval [CI] 0.31–0.80), decreased amount of RBC units (β unstandardised coefficient −1.42, 95 % CI −2.06 to −0.77) and decreased risk of transfusion of more than 2 RBC units (OR 0.53, 95 % CI 0.38–0.73).
    [Show full text]
  • The Potential Role of Recombinant Activated FVII in the Management of Critical Hemato-Oncological Bleeding: a Systematic Review
    Bone Marrow Transplantation (2007) 39, 729–735 & 2007 Nature Publishing Group All rights reserved 0268-3369/07 $30.00 www.nature.com/bmt REVIEW The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review M Franchini1, D Veneri2 and G Lippi3 1Servizio di Immunoematologia e Trasfusione – Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy; 2Dipartimento di Medicina Clinica e Sperimentale, Sezione di Ematologia, Universita` di Verona, Verona, Italy and 3Dipartimento di Scienze Biomediche e Morfologiche, Istituto di Chimica e Microscopia Clinica, Universita` di Verona, Verona, Italy Recombinant activated factor VII (rFVIIa) is an hemo- situations unresponsive to conventional therapy to control static agent that was originally developed for the excessive bleeding and reduce exposure to allogeneic blood. treatment of hemorrhage in patients with hemophilia and These include intracerebral hemorrhage, oral anticoagu- inhibitors.However, in the last few years rFVIIa has been lant-induced hemorrhage, thrombocytopenia, bleeding employed with success in a broad spectrum of congenital associated with hepatic failure, major surgery, trauma and acquired bleeding conditions.In this systematic review and life-threatening obstetrical, and gynecologic hemor- we present the current knowledge on the use of this drug in rhagic complications.5–9 patients suffering from hemato-oncological disorders, In this systematic review we have collected the available which are quite commonly complicated by severe hemor- data from the literature on the use of rFVIIa in hemato- rhage.On the whole, data in the literature suggest a oncological patients with severe bleeding, unresponsive to potential role for rFVIIa in the management of bleeding standard therapy.
    [Show full text]
  • Multiple Technology Appraisal Avatrombopag and Lusutrombopag
    Multiple Technology Appraisal Avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure [ID1520] Committee papers © National Institute for Health and Care Excellence 2019. All rights reserved. See Notice of Rights. The content in this publication is owned by multiple parties and may not be re-used without the permission of the relevant copyright owner. NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE MULTIPLE TECHNOLOGY APPRAISAL Avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure [ID1520] Contents: 1 Pre-meeting briefing 2 Assessment Report prepared by Kleijnen Systematic Reviews 3 Consultee and commentator comments on the Assessment Report from: • Shionogi 4 Addendum to the Assessment Report from Kleijnen Systematic Reviews 5 Company submission(s) from: • Dova • Shionogi 6 Clarification questions from AG: • Questions to Shionogi • Clarification responses from Shionogi • Questions to Dova • Clarification responses from Dova 7 Professional group, patient group and NHS organisation submissions from: • British Association for the Study of the Liver (BASL) The Royal College of Physicians supported the BASL submission • British Society of Gastroenterology (BSG) 8 Expert personal statements from: • Vanessa Hebditch – patient expert, nominated by the British Liver Trust • Dr Vickie McDonald – clinical expert, nominated by British Society for Haematology • Dr Debbie Shawcross – clinical expert, nominated by Shionogi © National Institute for Health and Care Excellence 2019. All rights reserved. See Notice of Rights. The content in this publication is owned by multiple parties and may not be re-used without the permission of the relevant copyright owner. MTA: avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure Pre-meeting briefing © NICE 2019.
    [Show full text]
  • A Study on Ulinastatin in Preventing Post ERCP Pancreatitis
    International Journal of Advances in Medicine Vedamanickam R et al. Int J Adv Med. 2017 Dec;4(6):1528-1531 http://www.ijmedicine.com pISSN 2349-3925 | eISSN 2349-3933 DOI: http://dx.doi.org/10.18203/2349-3933.ijam20175083 Original Research Article A study on ulinastatin in preventing post ERCP pancreatitis R. Vedamanickam1, Vinoth Kumar2*, Hariprasad2 1Department of Medicine, 2Department of Gasto and Hepatology , SREE Balaji Medical College and Hospital, Chrompet, Chennai, Tamil Nadu, India Received: 19 September 2017 Accepted: 25 October 2017 *Correspondence: Dr. Vinothkumar, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: Pancreatitis remains the major complication of endoscopic retrograde cholangiopancreatography (ERCP), and hyperenzymemia after ERCP is common. Ulinastatin, a protease inhibitor, has proved effective in the treatment of acute pancreatitis. The aim of this study was to assess the efficacy of ulinastatin, compare to placebo study to assess the incidence of complication due to ERCPP procedure. Methods: In this study a randomized placebo controlled trial, patients undergoing the first ERCP was randomizing to receive ulinastatin one lakh units (or) placebo by intravenous infusion one hour before ERCP for ten minutes duration. Clinical evaluation, serum amylase, ware analysed before the procedure 4 hours and 24 hours after the procedure. Results: Total of 46 patients were enrolled (23 in ulinastatin and 23 in placebo group).
    [Show full text]
  • WO 2014/153004 Al 25 September 2014 (25.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2014/153004 Al 25 September 2014 (25.09.2014) P O P C T (51) International Patent Classification: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, A61L 27/58 (2006.01) A61L 27/52 (2006.01) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, PCT/US20 14/028622 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (22) International Filing Date: TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 14 March 2014 (14.03.2014) ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 61/785,477 14 March 2013 (14.03.2013) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (71) Applicant: MEDICUS BIOSCIENCES LLC [US/US]; MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 2528 Qume Dr., Unit #1, San Jose, CA 95 13 1 (US).
    [Show full text]
  • Antiproteases in Preventing Post-ERCP Acute Pancreatitis
    JOP. J Pancreas (Online) 2007; 8(4 Suppl.):509-517. ROUND TABLE Antiproteases in Preventing Post-ERCP Acute Pancreatitis Takeshi Tsujino, Takao Kawabe, Masao Omata Department of Gastroenterology, Faculty of Medicine, University of Tokyo. Tokyo, Japan Summary there is no other randomized, placebo- controlled trial on ulinastatin under way. Pancreatitis remains the most common and Large scale randomized controlled trials potentially fatal complication following revealed that both the long-term infusion of ERCP. Various pharmacological agents have gabexate and the short-term administration of been used in an attempt to prevent post-ERCP ulinastatin may reduce pancreatic injury, but pancreatitis, but most randomized controlled these studies involve patients at average risk trials have failed to demonstrate their of developing post-ERCP pancreatitis. efficacy. Antiproteases, which have been Additional research is needed to confirm the clinically used to manage acute pancreatitis, preventive efficacy of these antiproteases in would theoretically reduce pancreatic injury patients at a high risk of developing post- after ERCP because activation of proteolytic ERCP pancreatitis. enzymes is considered to play an important role in the pathogenesis of post-ERCP pancreatitis. Gabexate and ulinastatin have Introduction recently been evaluated regarding their efficacy in preventing post-ERCP ERCP is widely performed for the diagnosis pancreatitis. Long-term (12 hours) infusion of and management of various pancreaticobiliary gabexate significantly decreased the incidence diseases. Early complications after ERCP of post-ERCP pancreatitis; however, no include acute pancreatitis, bleeding, prophylactic effect was observed for short- perforation, and infection (cholangitis and term infusion (2.5 and 6.5 hours). These cholecystitis) [1, 2]. Of these ERCP-related results may be due to the short-life of complications, pancreatitis remains the most gabexate (55 seconds).
    [Show full text]
  • Alternatives and Adjuncts to Blood Transfusion
    Joint United Kingdom (UK) Blood Transfusion and Tissue PDF Generated JPAC Transplantation Services Professional Advisory Committee 02/10/2021 03:05 Transfusion Handbook Update 6: Alternatives and adjuncts to blood transfusion http://www.transfusionguidelines.org/transfusion-handbook-update/6-alternatives-and-adjuncts-to-blood-transfusion 6: Alternatives and adjuncts to blood transfusion Essentials Transfusion alternatives were mostly developed to reduce blood use in surgery but have much wider application. They are most effective when used in combination and as part of a comprehensive patient blood management programme. Predeposit autologous blood donation before surgery is of uncertain benefit and now has very restricted indications in the UK. Intraoperative cell salvage (ICS) is effective (and may be life-saving) in elective or emergency high blood loss surgery and management of major haemorrhage. Postoperative cell salvage (PCS) and reinfusion can reduce blood use in joint replacement and scoliosis surgery. ICS and PCS are usually acceptable to Jehovah’s Witnesses. Tranexamic acid (antifibrinolytic) is inexpensive, safe and reduces mortality in traumatic haemorrhage. It reduces bleeding and transfusion in many surgical procedures and may be effective in obstetric and gastrointestinal haemorrhage. Off-label use of recombinant activated Factor VII (rFVIIa) for haemorrhage does not reduce mortality and can cause serious thromboembolic complications. Erythropoiesis stimulating agents (ESAs), such as erythropoietin, are standard therapy in renal anaemia and can support blood conservation in some cancer chemotherapy patients and autologous blood donation programmes. They may also be effective in selected patients with myelodysplasia. ESAs may cause hypertension and thromboembolic problems. Careful monitoring is required to keep the haematocrit below 35%.
    [Show full text]
  • Beverly, A., Ong, G., Wilkinson, KL, Doree, C., Welton, NJ, & Estcourt, LJ
    Beverly, A., Ong, G., Wilkinson, K. L., Doree, C., Welton, N. J., & Estcourt, L. J. (2019). Drugs to reduce bleeding and transfusion in adults undergoing cardiac surgery: A systematic review and network meta analysis. Cochrane Database of Systematic Reviews, 2019(9), [CD013427]. https://doi.org/10.1002/14651858.CD013427 Publisher's PDF, also known as Version of record Link to published version (if available): 10.1002/14651858.CD013427 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Cochrane Collaboration at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013427/full . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ Cochrane Database of Systematic Reviews Drugs to reduce bleeding and transfusion in adults undergoing cardiac surgery: a systematic review and network meta- analysis (Protocol) Beverly A, Ong G, Wilkinson KL, Doree C, Welton NJ, Estcourt LJ Beverly A, Ong G, Wilkinson KL, Doree C, Welton NJ, Estcourt LJ. Drugs to reduce bleeding and transfusion in adults undergoing cardiac surgery: a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2019, Issue 9. Art. No.: CD013427. DOI: 10.1002/14651858.CD013427. www.cochranelibrary.com Drugs to reduce bleeding and transfusion in adults undergoing cardiac surgery: a systematic review and network meta-analysis (Protocol) Copyright © 2019 The Cochrane Collaboration.
    [Show full text]
  • Role, Laboratory Assessment and Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis
    International Journal of Molecular Sciences Review Role, Laboratory Assessment and Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis Vassilios P. Memtsas 1, Deepa R. J. Arachchillage 2,3,4 and Diana A. Gorog 1,5,6,* 1 Cardiology Department, East and North Hertfordshire NHS Trust, Stevenage, Hertfordshire SG1 4AB, UK; [email protected] 2 Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London SW7 2AZ, UK; [email protected] 3 Department of Haematology, Imperial College Healthcare NHS Trust, London W2 1NY, UK 4 Department of Haematology, Royal Brompton Hospital, London SW3 6NP, UK 5 School of Life and Medical Sciences, Postgraduate Medical School, University of Hertfordshire, Hertfordshire AL10 9AB, UK 6 Faculty of Medicine, National Heart and Lung Institute, Imperial College, London SW3 6LY, UK * Correspondence: [email protected]; Tel.: +44-207-0348841 Abstract: Diseases such as myocardial infarction, ischaemic stroke, peripheral vascular disease and venous thromboembolism are major contributors to morbidity and mortality. Procoagulant, anticoagulant and fibrinolytic pathways are finely regulated in healthy individuals and dysregulated procoagulant, anticoagulant and fibrinolytic pathways lead to arterial and venous thrombosis. In this review article, we discuss the (patho)physiological role and laboratory assessment of fibrin, factor XIII and endogenous fibrinolysis, which are key players in the terminal phase of the coagulation cascade and fibrinolysis. Finally, we present the most up-to-date evidence for their involvement in Citation: Memtsas, V.P.; various disease states and assessment of cardiovascular risk. Arachchillage, D.R.J.; Gorog, D.A. Role, Laboratory Assessment and Keywords: factor XIII; fibrin; endogenous fibrinolysis; thrombosis; coagulation Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis.
    [Show full text]
  • HTRS 2021 Scientific Symposium PRELIMINARY VIRTUAL MEETING AGENDA
    HTRS 2021 Scientific Symposium PRELIMINARY VIRTUAL MEETING AGENDA HTRS Research Colloquium: March 8-9 FWGBD Colloquium: March 9 Multidisciplinary Pre-Conference: March 10-11 Agenda: Day 1 | Day 2 Agenda Agenda: Day 1 | Day 2 HTRS Scientific Symposium: March 10-12 Agenda: Day 1 | Day 2 | Day 3 MONDAY, MARCH 8, 2021 HTRS Research Colloquium: Day 1 – separate registration required Eastern Time Event 12:30 PM – 1:00 PM ET PRE-MEETING NETWORKING “BRING YOUR OWN LUNCH” 1:00 PM ET OPENING REMARKS Wolfgang Bergmeier, PhD, and Margaret V. Ragni, MD, MPH, 2021 Colloquium Co-Chairs 1:05 PM – 1:50 PM ET PLENARY SESSION: “HOW DO I BEGIN, AND WHO IS GOING TO PAY FOR THIS?” RESEARCH FUNDING TRENDS AND OPPORTUNITIES Moderator: Margaret V. Ragni, MD, MPH Speaker: Andrei Kindzelski, MD, National Institutes of Health (NIH) 1:50 PM – 2:20 PM ET NETWORKING BREAK -OR- MENTORING SESSIONS 2:20 PM – 3:20 PM ET PANEL PRESENTATION: “GETTING A JOB – A RECRUITER’S PERSPECTIVE” Moderator: Wolfgang Bergmeier, PhD 2:20 PM BASIC SCIENCE PERSPECTIVE James Morrissey, PhD, Professor, University of Michigan 2:35 PM CLINICAL SCIENCE PERSPECTIVE Janis Abkowitz, PhD, Professor, Hematology Division Head, University of Washington 1 HTRS Research Colloquium: Day 1 – continued Eastern Time Event 2:50 PM TRANSLATIONAL SCIENCE PERSPECTIVE Jorge Di Paola, MD, Professor/Division Chief, Washington University in St. Louis 3:05 PM INDUSTRY PERSPECTIVE Robert Peters, PhD, Sanofi Genzyme 3:20 PM – 4:00 PM ET ROUNDTABLE DISCUSSIONS • Basic Science Tables • Clinical Science Tables • Translational Science Tables • Population Science Tables 4:00 PM ET DAY ONE PROGRAM ENDS Session resumes Tuesday, March 9 at 12:30 PM ET TUESDAY, MARCH 9, 2021 FWGBD Colloquium on Uterine Hemostasis – separate registration required Eastern Time Event 9:30 AM – 9:45 AM ET CONVENE AND WELCOME Andra H.
    [Show full text]